Viret Jean-Frederic 4

What Happened
Jean‑Frederic Viret, Chief Financial Officer of SpyGlass Pharma, was granted a derivative equity award covering 17,500 shares on February 5, 2026. The Form 4 reports an acquisition price of $0.00 (code A — award/grant). The award is structured as shares subject to an option per the filing footnote.

Key Details

• Transaction date: February 5, 2026; Form 4 filed February 9, 2026 (timely within the 2-business-day reporting window).
• Reported acquisition: 17,500 shares, price reported $0.00 (derivative grant; transaction code A).
• Shares owned after transaction: Not disclosed on the provided data.
• Footnote (vesting): Vesting Commencement Date = February 5, 2026. 25% of the shares vest on the one‑year anniversary, then 1/48th of the shares vest each month thereafter on the same day (or last day of month if no corresponding day).
• No indication of immediate sale or tax withholding in this filing.

Context
This was a derivative equity grant (an option-style award per the footnote) rather than an open-market purchase or sale. Such grants are commonly part of executive compensation and only convert into owned shares as they vest and, if applicable, upon exercise. The filing was submitted on schedule and does not by itself indicate a buy or sell decision in the market.